BACKGROUND: The association of vitamin D status with prostate cancer is controversial; no association has been observed for overall incidence, but there is a potential link with lethal disease. METHODS: We assessed prediagnostic 25-hydroxyvitamin D [25(OH)D] levels in plasma, variation in vitamin D-related genes, and risk of lethal prostate cancer using a prospective case-control study nested within the Health Professionals Follow-up Study. We included 1260 men who were diagnosed with prostate cancer after providing a blood sample in 1993-1995 and 1331 control subjects. Men with prostate cancer were followed through March 2011 for lethal outcomes (n = 114). We selected 97 single-nucleotide polymorphisms (SNPs) in genomic regions with high linkage disequilibrium (tagSNPs) to represent common genetic variation among seven vitamin D-related genes (CYP27A1, CYP2R1, CYP27B1, GC, CYP24A1, RXRA, and VDR). We used a logistic kernel machine test to assess whether multimarker SNP sets in seven vitamin D pathway-related genes were collectively associated with prostate cancer. Tests for statistical significance were two-sided. RESULTS: Higher 25(OH)D levels were associated with a 57% reduction in the risk of lethal prostate cancer (highest vs lowest quartile: odds ratio = 0.43, 95% confidence interval = 0.24 to 0.76). This finding did not vary by time from blood collection to diagnosis. We found no statistically significant association of plasma 25(OH)D levels with overall prostate cancer. Pathway analyses found that the set of SNPs that included all seven genes (P = .008) as well as sets of SNPs that included VDR (P = .01) and CYP27A1 (P = .02) were associated with risk of lethal prostate cancer. CONCLUSION: In this prospective study, plasma 25(OH)D levels and common variation among several vitamin D-related genes were associated with lethal prostate cancer risk, suggesting that vitamin D is relevant for lethal prostate cancer.
BACKGROUND: The association of vitamin D status with prostate cancer is controversial; no association has been observed for overall incidence, but there is a potential link with lethal disease. METHODS: We assessed prediagnostic 25-hydroxyvitamin D [25(OH)D] levels in plasma, variation in vitamin D-related genes, and risk of lethal prostate cancer using a prospective case-control study nested within the Health Professionals Follow-up Study. We included 1260 men who were diagnosed with prostate cancer after providing a blood sample in 1993-1995 and 1331 control subjects. Men with prostate cancer were followed through March 2011 for lethal outcomes (n = 114). We selected 97 single-nucleotide polymorphisms (SNPs) in genomic regions with high linkage disequilibrium (tagSNPs) to represent common genetic variation among seven vitamin D-related genes (CYP27A1, CYP2R1, CYP27B1, GC, CYP24A1, RXRA, and VDR). We used a logistic kernel machine test to assess whether multimarker SNP sets in seven vitamin D pathway-related genes were collectively associated with prostate cancer. Tests for statistical significance were two-sided. RESULTS: Higher 25(OH)D levels were associated with a 57% reduction in the risk of lethal prostate cancer (highest vs lowest quartile: odds ratio = 0.43, 95% confidence interval = 0.24 to 0.76). This finding did not vary by time from blood collection to diagnosis. We found no statistically significant association of plasma 25(OH)D levels with overall prostate cancer. Pathway analyses found that the set of SNPs that included all seven genes (P = .008) as well as sets of SNPs that included VDR (P = .01) and CYP27A1 (P = .02) were associated with risk of lethal prostate cancer. CONCLUSION: In this prospective study, plasma 25(OH)D levels and common variation among several vitamin D-related genes were associated with lethal prostate cancer risk, suggesting that vitamin D is relevant for lethal prostate cancer.
Authors: Ivy Chung; Guangzhou Han; Mukund Seshadri; Bryan M Gillard; Wei-dong Yu; Barbara A Foster; Donald L Trump; Candace S Johnson Journal: Cancer Res Date: 2009-01-13 Impact factor: 12.701
Authors: Sarah K Holt; Erika M Kwon; Ulrike Peters; Elaine A Ostrander; Janet L Stanford Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05-19 Impact factor: 4.254
Authors: Jiyoung Ahn; Ulrike Peters; Demetrius Albanes; Mark P Purdue; Christian C Abnet; Nilanjan Chatterjee; Ronald L Horst; Bruce W Hollis; Wen-Yi Huang; James M Shikany; Richard B Hayes Journal: J Natl Cancer Inst Date: 2008-05-27 Impact factor: 13.506
Authors: Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Jiyoung Ahn; Demetrius Albanes; Sonja I Berndt; Ulrike Peters; Nilanjan Chatterjee; Neal D Freedman; Christian C Abnet; Wen-Yi Huang; Adam S Kibel; E David Crawford; Stephanie J Weinstein; Stephen J Chanock; Arthur Schatzkin; Richard B Hayes Journal: Carcinogenesis Date: 2009-03-02 Impact factor: 4.944
Authors: Haojie Li; Meir J Stampfer; J Bruce W Hollis; Lorelei A Mucci; J Michael Gaziano; David Hunter; Edward L Giovannucci; Jing Ma Journal: PLoS Med Date: 2007-03 Impact factor: 11.069
Authors: Ruth C Travis; Francesca L Crowe; Naomi E Allen; Paul N Appleby; Andrew W Roddam; Anne Tjønneland; Anja Olsen; Jakob Linseisen; Rudolf Kaaks; Heiner Boeing; Janine Kröger; Antonia Trichopoulou; Vardis Dilis; Dimitrios Trichopoulos; Paolo Vineis; Domenico Palli; Rosario Tumino; Sabina Sieri; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; María-Dolores Chirlaque; Aurelio Barricarte; Nerea Larrañaga; Carlos A González; Marcial V Argüelles; Maria-José Sánchez; Pär Stattin; Göran Hallmans; Kay-Tee Khaw; Sheila Bingham; Sabina Rinaldi; Nadia Slimani; Mazda Jenab; Elio Riboli; Timothy J Key Journal: Am J Epidemiol Date: 2009-04-09 Impact factor: 4.897
Authors: Johanna E Torfadottir; Thor Aspelund; Unnur A Valdimarsdottir; Mary Frances Cotch; Laufey Tryggvadottir; Tamara B Harris; Vilmundur Gudnason; Hans-Olov Adami; Lorelei A Mucci; Edward L Giovannucci; Meir J Stampfer; Laufey Steingrimsdottir Journal: Cancer Causes Control Date: 2019-02-25 Impact factor: 2.506
Authors: Song Yao; Stephen A Haddad; Qiang Hu; Song Liu; Kathryn L Lunetta; Edward A Ruiz-Narvaez; Chi-Chen Hong; Qianqian Zhu; Lara Sucheston-Campbell; Ting-Yuan David Cheng; Jeannette T Bensen; Candace S Johnson; Donald L Trump; Christopher A Haiman; Andrew F Olshan; Julie R Palmer; Christine B Ambrosone Journal: Int J Cancer Date: 2015-12-28 Impact factor: 7.396
Authors: Stephanie J Weinstein; Alison M Mondul; Kai Yu; Tracy M Layne; Christian C Abnet; Neal D Freedman; Racheal Z Stolzenberg-Solomon; Unhee Lim; Mitchell H Gail; Demetrius Albanes Journal: Eur J Epidemiol Date: 2018-08-02 Impact factor: 8.082
Authors: Hui Liu; Irene M Shui; Elizabeth A Platz; Lorelei A Mucci; Edward L Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-19 Impact factor: 4.254
Authors: Wei Wang; Sue Ann Ingles; Gabriela Torres-Mejía; Mariana C Stern; Frank Z Stanczyk; Gary G Schwartz; David O Nelson; Laura Fejerman; Roger K Wolff; Martha L Slattery; Esther M John Journal: Int J Mol Epidemiol Genet Date: 2014-02-17
Authors: Ting-Yuan David Cheng; Irena B King; Matt J Barnett; Christine B Ambrosone; Mark D Thornquist; Gary E Goodman; Marian L Neuhouser Journal: Am J Epidemiol Date: 2013-03-27 Impact factor: 4.897